Infectious Disease
Cryptococcal Meningitis
19
Pipeline Programs↗
1
Active Trials↗
13
Companies Involved↗
Cryptococcal Meningitis is an emerging landscape with 19 programs across 13 companies. The most active players are Prism Pharmaceuticals, Novartis, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 14
Phase 27
Phase 33
Approved
No programs
Analysis
Trial Status
34
clinical trials
Completed24 · 71%
Unknown status7 · 21%
Terminated2 · 6%
Enrolling by invitation1 · 3%
Clinical Trials
Trial Activity
34 trials
Dexamethasone in Cryptococcal Meningitis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000776·36 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)